Meet 2019’s newest biotech unicorn — Gossamer Bio — which is making its debut on Nasdaq Friday with an upsized $276 million offering.
The drug developer — with a valuation of $1 billion, according to Renaissance Capital — is run by former Receptos executives, and follows the year’s first unicorn Alector $ALEC that raised $176 million at a $19 midpoint price. Investors are eagerly anticipating the performance of both, with an eye on other IPO’s waiting in line, after a turbulent December ravaged stocks across the boar
